| Autor: |
Boghdadly, Z.E., Pergam, S.A., Papanicolaou, G., Shahid, Z., Waghmare, A., Wingard, J.R., Chemaly, R.F., Boeckh, M., Abidi, M.Z., Khawaja, F., Hill, J.A., Michaels, L., Auletta, J.J., Dadwal, S., Kamboj, M. |
| Rok vydání: |
2023 |
| DOI: |
10.17615/1wg8-1818 |
| Popis: |
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disproportionately affects immunocompromised and elderly patients. Not only are hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell recipients at greater risk for severe COVID-19 and COVID-19–related complications, but they also may experience suboptimal immune responses to currently available COVID-19 vaccines. Optimizing the use, timing, and number of doses of the COVID-19 vaccines in these patients may provide better protection against SARS-CoV-2 infection and better outcomes after infection. To this end, current guidelines for COVID-19 vaccination in HCT and CAR T-cell recipients from the American Society of Transplantation and Cellular Therapy Transplant Infectious Disease Special Interest Group and the American Society of Hematology are provided in a frequently asked questions format. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
